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The ability to construct in vitro models of biologic events has lead to considerable 
knowledge about the immune response. Govaerts (1) and Rosenau and Moon (2) were 
among  the first to  describe feasible in vitro systems for the  study of cell-mediated 
immunity (CMI) ~ and their reports initiated much of the subsequent activity in this 
area. Since then, models for the study of CMI or of delayed hypersensitivity (DH) 
have been the subject of considerable effort and a number of promising in vitro models 
have  been proposed. The  subject of these  models can  be  divided broadly into  the 
following groups:  (a)  elaboration of mediator  factors  by cells involved in  delayed 
hypersensitivity inclu~ting  transfer  factor  (3),  migration-inhibition factor  (4),  pro- 
liferation-inhibition factor  (5),  transforming or blastogenic factor  (6),  lymphotoxin 
(7), chemotactic factors (8), and interferon (9); (b) cellular reactions (clonal prolifera- 
tion, blast transformation, stimulation of deoxyribonucleic acid [DNA] synthesis) to 
antigens or mitogens (phytohemagglutinin [PHA], poke weed mitogen) in lymphocyte 
culture (10  12); and (c) target cell destruction by the activated lymphocyte (13-15). 
This  last experimental system dealing with  target cell destruction by lymphocytes 
has  provided an  impetus  to  the  study  of  mechanisms  of  graft  rejection and  their 
modification. 
One manner of modifying the rejection of a graft in vivo has been through the use of 
immune  serum with specificities directed against the graft  (16).  Application of this 
phenomenon,  termed enhancement,  has  effected prolonged or indefinite survival of 
grafts which otherwise would have been rejected (17-19). Until recently the study of 
enhancement has been restricted largely to in vivo models although notable exceptions 
do exist (see Discussion). 
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Lymphocyte-mediated cytotoxicity (LCT) in vitro has been used as a model for ex- 
ploring the effects of normal serum, immune serum, or serum from tumor-bearing ani- 
mals on CMI. To date,  however, it has not been demonstrated specifically that en- 
hancement in vivo and inhibition of LCT in vitro are the same phenomenon dependent 
upon the same mechanisms and factors. It is reasonable to assume that these are similar 
expressions of the same process and as such would depend upon identical mechanisms 
and serum factors. It is the purpose of the experiments reported here to test this hy- 
pothesis. 
In a  previous study in this laboratory (20)  it was shown that  enhancement 
was mediated by antigen-antibody complexes and that these complexes exerted 
an effect on the lymph node cells (20,  21). These cells could be obtained either 
from immunized or from unimmunized animals. At this point, it seemed appro- 
priate  to  extend  these  observations  to  an  in vitro model in  which  one  could 
simplify the number of reactants  and determine whether or not the same sera 
which were active in vivo were also active in vitro. Further, the role of antigen- 
antibody complexes could be tested in vitro in  the light of the previous work 
demonstrating the participation of these complexes in the mediation of enhance- 
ment  in vivo. We  describe  here  an  in  vitro model for  studying  lymphocyte- 
mediated  cytotoxic effects on  tumor  cells and  report  the ability of microliter 
volumes of antisera with known enhancing activity in vivo to be active in this 
in vitro model. The action both in vitro and in vivo is dependent upon the forma- 
tion of antigen-antibody complexes. 
Materials and Methods 
Mice, Tumor, Sera, and Immunizatlon.--The  anti-BP8  sera, the BP8  ascites tumor,  and 
the mouse strains  employed have  all been characterized  and  described previously  (20). All 
sera were heated  (56°C for 30 rain) before use. Briefly, BP8 is an ascites tumor which is histo- 
compatible  for  C3H  (H-2k) mice and  the tumor is maintained  by weekly intraperitoneal 
inoculation into these mice. C57BL mice are resistant  to the tumor, being H-2b. These latter 
mice were used as donors of normal or immune lymph node cells (ILNC). Immunization  was 
performed by injecting  106 cells subcutaneously in each  limb and in  each lateral  chest wall 
(total, 6 X 106 cells), or mice were immunized intravenously by injecting 2-3 X 106 cells into 
the lateral  tail vein.  Control  mice were injected  subcutaneously  with 0.02 ml of complete 
F'reund's adjuvant into each limb and each lateral chest wall. 
Tissue Culture Media.--The basic medium was RPMI-1640, each 100 ml of which was sup- 
plemented with 20 mg of L-arginine, 0.2 mM of L-glutamine, 10,000 units  of potassium Peni- 
cillin G, 10 mg of ampicillin, and  10 ml of IPT-fetal calf serum (heated to 56°C for 30 rain). 
RPMI-1640, glutamine, and IPT-fetal calf serum (certified free of gamma globulin, tested by 
immunoprecipitation)  were obtained from Grand Island  Biological Company,  Grand Island, 
N. Y. The arginine solution was prepared from the dry reagent  (Schwarz Bio Research Inc., 
Orangeburg,  N. Y.).  Penicillin  G  (Pfizer Lab.  Division, New York)  and ampicillin  (Ayerst 
Laboratories, New York) were standard  pharmaceutical  preparations  for human use. 
Culture Conditions.--Cells were  cultured  in  screw-capped  16-  X  100-ram sterile  tubes. 
These were incubated vertically in a 30°C water bath without  shaking or rocking. The stand- 
ard  culture  volume was 2 ml, although  in a few instances,  1-ml cultures  were used. Tubes 1240  LYMPHOCYTE-MEDIATED  CYTOTOXICITY  IN  VITRO 
were autoclaved immediately before use. A series of experiments was carried out at tempera- 
tures of 26  °, 28  °, 30  °, 32  °, 34  °, and 37°C to determine the temperature optimum for this cul- 
ture system. It was found that 30°C yielded the most reproducible, reliable system. 106 tumor 
ceils were used/ml of culture and concentrations of lymph node cells (LNC)  ranged  from  1 
to 24  >(  106/ml. Concentrations of spleen cells ranged from 5 to 80  )<  106/ml. 
Preparation  of Cell  Suspensions.--For  all  preparation  and  dissection,  sterile  glassware, 
instruments, and solutions were used throughout. 
Tumor:  A  tumor-bearing C3H  mouse was killed  by cervical  luxation and mounted ab- 
domen up on an operating board. The fur was thoroughly wetted with 70% alcohol and with 
the aid of fine scissors the skin was reflected back to expose the peritoneal surface. Then a 
clamp was fastened to the linea alba and the peritoneum was tented upward with traction 
on the clamp. A  syringe and needle were used to draw the tumor cell-containing ascites fluid 
from the abdomen. This was placed in a  capped test tube and washed three times with bar- 
bital buffer (pH 7.4). Mter determining the tumor cell concentration, a  suspension of 4  or 8 
X  106 tumor cells/ml was prepared  in culture medium. Aliquots of 0.5 or 0.25 ml were dis- 
pensed to each culture tube. This yielded a  total of 2  )<  106 tumor ceils. 
Lymphoid cells:  Subcutaneously immunized or normal mice were killed and mounted for 
dissection as above.  The skin was reflected  and  the axillary,  brachiai,  and inguinal lymph 
nodes were removed and placed in a  Petri dish. Mice that had been immunized intravenously 
were treated similarly but, in addition, the mesenteric and cervical lymph nodes were removed 
and  added  to the other  nodes.  Spleens were  removed and placed  in a  separate Petri  dish. 
Single cell suspensions were prepared by teasing the lymph nodes apart with a 20 gauge needle 
and fine forceps. Spleen ceils were prepared by incising the capsule and gently expressing the 
contents by kneeding the spleen with  the flat part  of a  small scissors. Both the  LNC  and 
spleen cells were then expressed gently through a  22  then a  25 gauge needle. After this, the 
cells were washed three times in medium. Cells were counted in a  Neubauer chamber with 
trypan blue exclusion used to determine cell viability. At least 90% of ceils were usually viable 
and cell suspensions were not used ff less than 90% of the cells were viable. 
Cell Enumeration.--At  various time intervals, samples were withdrawn from the culture 
and the per cent of viable cells determined. The time periods at which samples were taken 
varied from 0  to 40 hr. The tubes were mixed well and 0.1 ml of the culture suspension was 
withdrawn using an Oxford pipette and sterile plastic tip. This was added to 0.1 cc of 0.3% 
trypan blue and the total number of cells and the number of dead cells were determined in a 
Neubauer chamber. Results are expressed  either as the per cent of viable tumor cells or the 
per cent of dead tumor cells. Per cent  of dead tumor cells is also referred to as per cent of 
cytotoxicity. The results are given for the cells in culture at a given sample time. Differentia- 
tion of tumor cells from LNC is quite easy as the tumor  cells are at least three to four times 
as large as the LNC (22). 
Interactio~  of Antibody and  Tumor Cdls.--In  the first set of experiments, 1 or 10/zl of an 
anti-BP8 antiserum (the designations for the two different anti-BP8 antisera with known en- 
hancing activity in vivo are "BH" and "669")  were added to test cultures containing ILNC 
and  tumor cells. Similar quantities of normal mouse serum  (NMS)  which had been heated 
(56°C for 30 rain) were added to control cultures with the same number of ILNC and tumor 
cells. In the second set of experiments, 10 #l of an anti-BP8 antiserum were added to 0.2 ml 
of tumor cell suspension (2  >(  106 tumor cells) and 0.8 ml of medium (in duplicate). The mix- 
ture was allowed to incubate at room temperature for 45 rain. The cells were sedimented by 
centrifugation and the supernatant saved. The cells were washed twice with cold  (4°C)  me- 
dium and retained. These are referred to as washed tumor-antibody complexes. To the super- 
natant was added 0.25 ml which contained 46 >( 10  ~ tumor cells, and the mixture was allowed 
to incubate for 45 min at room temperature. The cells were then sedimented and the super- 
natant saved as "absorbed antibody." This entire volume was added to a  culture of immune 
lymph node cells and tumor cells. WILLIAM  J.  KLEIN~  JR.  1241 
10/zl of antibody were allowed to incubate with immune lymph node cells for 45 min as 
in the first step above. The lymph node cells were then washed twice and used in the LCT 
assay as a control for the immune lymph node cells that had been exposed to tumor-antibody 
complexes (above). 
Test for Lymphotoxin Activity.--The methods of Granger et al, (7, 23, 24) were employed 
for collecting and storing supernatants from cultures of tumor cells with immune or normal 
LNC, tumor cells with immune spleen ceils, or from cultures of tumor cel]s alone. They were 
tested on HeLa cell monolayers. 
RESULTS 
Normal and Immune C57BL LNC.--Fig. 1 shows the results of culturing BP8 
tumor cells alone or in combination with normal or immune C57BL LNC. In 
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Fro. 1.  Per  cent viable tumor cells remaining in cultures of  (k--A) tumor cells only 
O--O, tumor cells ~ith normal C57BL LNC; Q--O, tumor cells with immune C57BL LNC 
this experiment, immune  LNC came from animals killed 5 days after subcutane- 
ous immunization and were cultured at a  concentration of 13.5  X  106/ml. In 
other experiments, immune  LNC were employed at concentrations  ranging from 
1 X  106/rot to 24 X  106/ml (see below). Normal LNC (NLNC) were employed 
at concentrations up to 40 X  106/ml. All concentrations of normal LNC gave 
similar results and the curve shown is for the highest concentration. The maxi- 
mum cytotoxicity observed with normal LNC was 21% (37 X  106 NLNC/ml). 
With the exception of this single experiment, seven other assays with NLNC 
gave 10% cytotoxicity or less. The mean cytotoxicity observed for all experi- 
ments with NLNC was 6.4 with a standard error of 2.35 %. 
Control  Cell Suspensions.--Fig.  2 depicts the results obtained when normal 1242  LYMPHOCYTE-MEDIATED  CYTOTOXICITY  IN  VITRO 
C3H LNC, C3H LNC from tumor-bearing animals, and LNC taken from ani- 
mals 5  or  7 days after injection with  Freund's adjuvant  were  tested  against 
tumor cells in this system (the results are shown for LNC taken from animals 5 
days after injection of Freund's adjuvant, but the results Dora animals 7 days 
after imnmnization are not different). It can be seen that none of these control 
LNC is capable of effecting tumor cell cytotoxicity in this system. The mean 
cytotoxicity observed in all experiments using these control cell suspensions was 
5.2 % with a standard error of 1.6 %. Immune (5 or 7 day postinjection) or nor- 
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FIo. 2.  Per cent viable tumor cells remaining in cultures of (A--A) tumor cells only; 
• --•, tumor cells with normal C3H LNC; A--ZX, tumor cells with LNC from tumor-bear- 
ing C3H; O--O, tumor cells with LNC from C57BL 5 days after immunization with Freund's 
adjuvant. 
real  C57BL spleen  cells  are  also  incapable  of expressing  cytotoxicity in  this 
system. 
Kinetics of Cytotoxicity.--The results of studying the kinetics of this reaction 
are shown in Fig. 3. Samples were taken at 0, 2, 4, 8, 12, 14, 16, 20, 24, 28, and 
30 hr after the initiation of the culture. In this experiment, as in others, definite 
cytotoxicity did not appear until  after the  19th hr of culture and progressed 
rapidly thereafter. Maximum cytotoxicity was reached usually by the 26th  30th 
hr. After initial experiments in which the time course of the cytotoxic reaction 
was studied and defined,  subsequent experiments employed two to three samples 
taken after  18 hr of culture in  order to determine the presence or absence of 
LCT. Incubation of control lymphocytes with tumor cells for longer periods of WILLIAM  J.  KLEIN,  JR.  1243 
time (40 hr) did not alter the results. The addition of guinea pig complement to 
normal or immune LNC cultures did not change the per cent of dead cells and 
did not alter the kinetics. 
Lymphocyte: Target Cell Ratio.--Fig.  4  illustrates  the  results  obtained  with 
various lymphocyte: target cell ratios. The ILNC were obtained from animals 
5 days after immunization. Since the concentration of tumor cells is 1 X  106/ml, 
the ratio is also the concentration (in millions) of LNC per milliliter.  Cytotoxic- 
ity was observed at ratios as low as 4.5 to 1, but ratios of 10:1 up to 24:1 were 
used in order to obtain reproducible results.  Nine separate  assays  (each assay 
tested one or more of six concentrations of ILNC) in duplicate have been per- 
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Fie. 3, Kinetics of cytotoxicity. Per cent viable tumor cells remaining in cultures of (0--0) 
tumor cells only; I--I,  tumor cells with 12 X  106 ILNC/ml. 
formed in this  range  (10-24: 1)  with  similar  results  (See Table I). All experi- 
ments were carried out with LNC from animals killed 5 or 7 days after subcuta- 
neous immunization. 
The Activity of LYC Obtained at Various Times after Immunization.--Animals 
were killed at 3, 5, 7, 9, 10, 11, 14, and 15 days after immunization and the LNC 
removed and tested for cytotoxic activity against the tumor cells. The results 
are shown in Fig. 5. Each experiment was performed  at least  twice. LNC are 
most active at 5 or 7 days postimmunization and yield 100% cytotoxicity con- 
sistently. There is no detectable cytotoxicity at days 3, 9, 11, 12, or 14. However, 
at 15 days after immunization there appears to be some measurable increase in 
LCT activity (average of two experiments)  as seen in Fig. 5. 
Effect of Enhancing  Sera.--The next  experiments  were designed  to test  the 
effect of known enhancing antisera  on LCT in vitro. Both sera  (see Materials 1244  LYMPHOCYTE-MEDIATED  CYTOTOXICITY  IN  VITRO 
and Methods section on interaction of antibody and tumor cells) used in these 
experiments have been shown previously to produce enhancement in vivo (20, 
21). Microliter quantities of these antisera were capable of abrogating lympho- 
cytotoxic activity in vitro. The results are shown in Fig. 6 for antisera BH and 
were not different for the other antiserum, No. 669. The addition of anfisera No. 
669 to cultures of ILNC and tumor cells resulted in 87 % viable cells at 29 hr of 
culture, whereas in the mixture of ILNC and tumor cells alone there were 19 % 
viable cells at this same time. Absorption of the sera with fresh BP8 tumor cells 
too 
2 "10  6 LNC/ml 
LNC/ml 
rn 
>  5o 
O~  06 LNC/ml 
20- 
,o 
20.t06 LNC/ml 
I  L  I  I  I  I  ~,,  I 
0  4  8  t2  ~6  20  24  28  32 
INCUBATION  TIME  IN  HOURS 
FIG. 4.  Per cent viable tumor cells remaining in cultures of tumor cells with various con- 
centrations  of immune LNC. 
before testing eliminated  the ability to suppress in vitro cytotoxicity. The in- 
hibition of LCT occurred when the antisera were added to the final culture mix- 
ture of ILNC and tumor cells. More notably, inhibition of lymphocytotoxic ac- 
tivity was seen when washed tumor-antibody complexes were mixed with the 
ILNC and cultured. In these experiments the tumor cells are treated with anti- 
body, washed, and then added to the ILNC. In order to determine whether the 
antibody-antigen  complexes  were  affecting  the  lymphoid  cells,  the  following 
control procedure was performed. Antibody was incubated with ILNC first, the 
lymphoid cells were then washed, and these cells were added to the tumor cells. 
No inhibition of ILNC cytotoxic activity was observed in these experiments. 
Most significantly, however, lymphocytes which were incubated with tumor- WILLIAM  J.  KLEIN,  JR.  1245 
antibody complexes, washed, and then added to fresh tumor cells which had not 
been  treated  with  antibody were  also incapable  of exhibiting  LCT. Normal 
mouse serum had no effect on LCT. 
Intravenous  Immunization.--In  another  series  of  experiments  an  alternate 
method of immunization, namely the intravenous route, was tested.  Cell  sus- 
pensions were obtained from the lymph nodes of mice killed 3, 5, 7, 9, 10, or 12 
days after intravenous immunization. A maximum LCT of 30 % was obtained 
with  lymphoid cell:tumor cell  ratios  of  20:1,  using  lymph nodes  from mice 
killed 12 days after immunization. No cytotoxicity of tumor cells was observed 
using lymph node cells obtained from 3 to 9 days after intravenous imnmniza- 
Result 
TABLE I 
of  Various  Lymphocyte:Tumor  Cdl 
Ratios on Tumor Cell Viability 
No. of ILNC/mI* (x  10-6)  Average per cent viable 
tumor cells 
24  (1)  0 
20  (3)  4 
18  (2)  13 
15  (2)  10 
14  (4)  2 
10  (4)  5 
8  (2)  4S 
5  (2)  65 
2  (3)  96 
0  (9)  98 
* All ILNC were obtained 5 or 7 days after 
immunization. All cultures had 106 tumor cells/ 
ml.  Number of experiments shown in paren- 
theses. 
tion. The use of LNC obtained 10 days postimmunization at concentrations of 
12 and 7.2 X  106/ml resulted in 22 % cytotoxicity and less than 5 % cytotoxicity, 
respectively. 
Comparison of Events In Vivo and In Vitro.--In order to evaluate the relation- 
ship of the events in vitro to those in vivo, a different and very virulent strain 
of BP8 tumor which had arisen from the original strain was employed. Whereas 
the C57BL mice previously were tolerating 106 cells intraperitoneally, this par- 
ticular BP8 tumor was lethal at this dose. Even at doses of 2 )<  105 cells, ap- 
proximately 25 % mortality was being observed. This strain of tumor was used 
for immunizing mice and for testing in the LCT assay described here. In eight 
different experiments performed in duplicate, no cytotoxic activity was present 
in lymph node cells obtained from mice 5-7 days after subcutaneous imnmniza- 1246  LYMPHOCYTE-MEDIATED  CYTOTOXICITY  IN  VITRO 
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FIG. 6.  Effect of antisera with known enhancing activity in vivo on LCT. Per cent viable 
tumor cells remaining in cultures of (O--O) tumor cells only; O--O, tumor cells with ILNC; 
A--A,  tumor cells with ILNC plus 10 #1 of "BH" antisera; A--A, tumor cells with ILNC 
plus 1/zl of "Bit" antisera; B--U, tumor cells with ILNC plus 10/zl of NMS. WILLIAM  J.  KLEIN,  JR.  1247 
tion. The results of these experiments are shown in Fig. 7. Thus, whatever the 
change in the tumor may have been, increased virulence in vivo was paralleled 
by a  loss of the ability of the lymph node cells from immunized animals to ex- 
press LCT in vitro. 
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ILNC. Results are shown as the mean -4- the standard error for eight experiments  in dupli- 
cate. 
TABLE II 
Counts Per Minute of Amino AcidJ4C Incorporated into Protein 
Amount of protein -14C 
Source of supernatant  Mean -2= range/2  synthesized (expressed 
as per cent of control) 
% 
Tumor cells alone  760  4-  39  100 (control) 
Tumor cells +  ISPC* (40 X  106/ml)  664  4-  82  87 
....  +  NLNC (20 X  106/ml)  812  -4-  187  107 
"  "  +  ILNC (19.4 X  106  ml)  94  4-  20  12 
....  +  ILNC (11  X  106/ml)  300  4-  150  39 
* ISPC, immune spleen cells. 
Test .for Lymphotoxin  Activity.--The  supernatant  culture fluid from various 
control cultures and from cultures of immune LNC with tumor cells were stored 
according to the method of Granger (7, 23, 24). They were tested for their ability 
to inhibit protein synthesis of HeLa cells in monolayer culture. The results of 
this testing are shown in Table II. All supernatants are supplemented with fetal 
calf serum, antibiotics, and vitamins (7, 23, 24). It can be seen that the super- 1248  LYMPHOCYTE-MEDIATED CYTOTOXICITY IN  VITRO 
natants from ILNC-tumor cell cultures possess lymphotoxin activity, i.e.,  the 
ability to inhibit protein synthesis in the tissue culture cells. These supernatant 
culture fluids, derived from the incubation of 19 X  106 ILNC/m], and 11 X  106 
ILNC/ml, resulted in the synthesis of only 12 and 39 % of the control amount of 
protein-~4C by the tissue culture cells. Supernatant fluids obtained from cultures 
of tumor cells alone, tumor cells plus immune spleen cells,  or tumor cells plus 
NLNC  did not result in depressed protein synthesis. The control cultures of 
NLNC or immune spleen cells did not demonstrate LCT in vitro either. 
DISCUSSION 
An in vitro model for studying the reaction of imnmne lymphocytes against 
BP8 ascites tumor cells and for determining the effect of known enhancing anti- 
sera on such interactions has been presented. The results of these experiments 
indicate that normal LNC or LNC obtained after immunization with Freund's 
adjuvant do not produce cytotoxicity, whereas specifically immune LNC sensi- 
tized in vivo are actively cytotoxic to the tumor cells. Lymphocytotoxic  activity 
as measured in this test is detectable in the lymph node cells only during the 
period of 5  7 days after immunization,  but does not require extremely high 
lymphocyte: target cell ratios. The ratios used here ranged from 5 to 24:1  with 
ratios of 10 to 24:1 yielding the most consistent results. 
Results with this model have certain implications concerning the effectiveness 
of different routes of immunization. A doubling of the dose of tumor cells ad- 
ministered intraperitoneally will result in the death of a significant number (ap- 
proximately 20%) of C57BL mice, yet they are able to tolerate 106 cells intra- 
peritoneally or, more notably, 6  X  106 cells when given subcutaneously. This 
suggests that subcutaneous immunization with its marked stimulation of re- 
gional lymphoid tissues is a more potent stimulus to cellular immunity in the 
lymph nodes  tested  (axillary, brachial,  and inguinal)  than is  intraperitoneal 
immunization. In the experiments using lymph node cells after intravenous im- 
munization, a maximum cytotoxicity of 30% was observed with LNC obtained 
12-15 days after intravenous immunization. No significant LCT was observed 
earlier than this. This is in contrast to 100 % cytotoxicity obtained with equal 
or lower concentrations of LNC harvested 5 or 7 days after subcutaneous im- 
munization. These observations also are  consistent with  the  concept of sub- 
cutaneous immunization being the most potent route for stimulation of CMI. 
The results obtained with the known enhancing antisera in vitro parallel those 
obtained with the very same sera in vivo (20, 21) and suggest that the in vitro 
system is, in fact, representative of the in vivo system. Furthermore, it would 
imply that abrogation of LCT in vitro is dependent upon the same mechanisms 
and serum factors as enhancement in vivo. Specifically, in both systems antigen- 
antibody complexes have been shown to be necessary for the mediation of en- 
hancement, while ILNC exposed to antibody alone remain fully active. The WILLIAM J.  KLEIN~ JR.  1249 
antigen-antibody complexes are able  to induce  a  change in  the ILNC which 
prevents them from attacking fresh untreated tumor cells. It would be of great 
importance to understand the biochemical alterations in the LNC which have 
been initiated by the antigen-antibody complexes. 
The parallel between events in vivo and those in vitro is further fortified by 
the data obtained using the virulent tumor which the C57BL mice were unable 
to reject at the usual dose. In vitro we found a similar event in that LNC ob- 
tained after subcutaneous injection with this virulent tumor strain did not ex- 
press any cytotoxicity. 
With regard to the mechanism of antibody-mediated immunosuppression, the 
results reported here are consistent with a central mechanism of enhancement, 
i.e., the afferent limb (recognition)  of the immune response has taken place in 
vivo and  the  effect of the  antigen-antibody  complexes is on  the  lymphocyte 
before it can become an effector cell.  The elimination of afferent inhibition  as 
the mechanism of low dose enhancement in vivo already has been suggested by 
the following observations: (a) The quantity of antiserum which will bring about 
enhancement is minute and would not be expected to cover all the binding sites. 
(b) Even if all the binding sites were covered they would not remain so at 37°C 
(20). The data obtained here, using cells which have undergone the recognition 
phase in vivo, add further support to the idea that enhancement must interact 
in either the central or efferent phase of the immune response. 
The experiments in which  ILNC are  exposed to washed,  antibody-treated 
tumor cells are the strongest evidence for a central mechanism of enhancement. 
These ILNC when incubated with fresh tumor cells which have never been ex- 
posed to antibody are unable to exhibit any cytotoxic activity and ILNC are 
not affected by incubation  with  antibody alone.  Thus we cannot explain  the 
lack of LCT on the basis of "covering up" of tumor antigen sites. This evidence, 
along with the above mentioned observations which tend to exclude an afferent 
mechanism,  would  indicate  that  antibody-induced  immunosuppression  must 
take place after antigen  recognition  and before the direct  attack of LNC  on 
tumor cells.  The effect is one of antigen-antibody complexes on the lymphoid 
cells themselves and is therefore central. 
The mechanism of the cytotoxicity in our assay and in others is not entirely 
clear. Most workers who have explored this question have indicated a require- 
ment for contact between the cells (25,  26). More recently Granger (7, 23,  24, 
27)  has developed evidence for the release into the medium of an effector sub- 
stance, termed lymphotoxin, which causes inhibition of cellular metabolism and 
eventual cell death. 
Testing the supernatants from our system we do, in fact, find evidence for the 
release of lymphotoxin. The supernatant culture fluid from immune LNC-tumor 
cell interaction inhibited protein synthesis in the target HeLa cells (Table II). 
No such inhibition of HeLa cell protein synthesis was obtained with superna- 1250  LYMPHOCYTE-MEDIATED CYTOTOXICITY  IN  VITRO 
tants from cultures of tumor cells alone,  tumor ceils incubated with immune 
spleen cells,  or tumor cells and NLNC. 
The relationship of LCT in vitro to lymphocyte transformation and delayed 
hypersensitivity is not clear. Although Chaparas et al. (28) dissociated DH from 
lymphocyte transformation using their carbohydrate material, it is not certain 
whether this can be done with protein antigens as well. Perlmann et al. (29) have 
separated LCT from lymphocyte transformation, but in our system the BP8 
tumor cells can elicit both LCT and stimulation of DNA synthesis in cultured 
C57BL lymph node cells (30). 
With regard to the relationship of lymphocyte transformation and lympho- 
toxin transformation production,  there is  preliminary data  in  this  laboratory 
which suggests that the stimulation of DNA synthesis is neither a necessary nor 
a  sufficient condition  for  the  production  of lymphotoxin activity.  Although 
Granger has shown that lymphotoxin production began before there was direct 
biochemical evidence of stimulation of DNA synthesis, he did not demonstrate 
that circumstances which lead to lymphotoxin production did not also lead, even 
if more remotely, to stimulation of DNA synthesis (23). 
The relationships of lymphotoxin production, LCT, and lymphocyte trans- 
formation remain open to question and are currently under study in this labora- 
tory. It is intriguing to wonder which if any of these processes, passively ad- 
ministered antibody might be capable of shutting off in vivo. Evidence from 
earlier experiments would  suggest  that  antibody does abrogate LCT in vivo 
(20). The use of passive antibody to prolong graft survival in humans and efforts 
to break enhancement in patients with neoplasia will require further knowledge 
about such basic phenomena. 
SUMMARY 
The ability of antisera to suppress immune responses either in vivo or in vitro 
is well known. A variety of lymphocyte-target cell systems have been employed 
to demonstrate inhibition of cell-mediated immunity by antisera in vitro, and 
skin,  tumor, and kidney graft survival have been prolonged by passively ad- 
ministered antiserum in vivo. An in vitro lymphocyte-tumor cell assay system 
was developed for the purpose of studying the effects of enhancing antisera (in 
vivo) on lymphocyte-mediated cytotoxicity in vitro. The characteristics of this 
system with respect to route of immunization, time of harvest of immune cells, 
lymphocyte: tumor cell ratio, and effect of nonimmune or nonspecifically im- 
mune lymphoid cells are presented. Sera capable of enhancement in vivo were 
tested in this system and  shown  to inhibit  cell-mediated immunity in vitro. 
Further, in both instances the immunosuppressive effect is mediated by antigen- 
antibody complexes and not by free antibody alone. 
Experiments were also carried out to determine the site of action of these sup- 
pressive antigen-antibody complexes. Presensitized lymphocytes were exposed WILLIAM J.  KLEIN,  JR.  1251 
to antigen-antibody complexes, washed, and then allowed to interact with fresh 
tumor  cells  (not  antibody treated).  Lymphocytes treated  in  this  manner  are 
incapable of exhibiting cell-mediated immunity in vitro. This evidence supports 
the concept that the antigen-antibody complexes have a direct immunosuppres- 
sive effect on the lymphocyte. 
The author is deeply indebted to Dr. D. B. Amos in whose laboratory these studies were 
performed. In addition to the generous use of his facilities, more importantly Dr. Amos was 
always readily  available  for stimulating  discussion,  comment,  and  criticism.  The author 
thanks Mrs. Mimie Davis for her expert technical assistance. 
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